{"success":true,"data":{"pressRelease":{"id":"141172","rtpr_id":"nWkr85c3LC-20260911","ticker":"CAMX","exchange":"Nasdaq Stockholm","all_tickers":["CAMX"],"title":"Camurus' Nomination Committee appointed for the Annual General Meeting 2027","author":"Cision","published_at":"2026-09-11T05:00:14.359Z","article_body":"Camurus AB\nLund, Sweden - 11 September 2026 - Camurus today announced that the Nomination\nCommittee for the Annual General Meeting (AGM) 2027 consists of the following\npersons, who together represent about 38 percent of the total number of shares\nand votes in Camurus based on the last known shareholder information:\n* Per Sandberg, appointed by Sandberg Development AB,\n* Arne Lööw, appointed by Fjärde AP-fonden,\n* Anna Henricsson, appointed by Handelsbanken Fonder, and\n* Per Olof Wallström, Chairman of the Board of Camurus\nThe Nomination Committee's proposals will be presented in the Notice to the\nAGM 2027 and on Camurus' website, www.camurus.com.\n\nShareholders who wish to submit proposals to the Nomination Committee are\nwelcome to contact the Nomination Committee at the company's address, Rydbergs\ntorg 4, SE-224 84, Lund, Sweden. Proposals shall be submitted in due time\nbefore the AGM, but not later than 11 February 2027, to ensure that the\nproposals can be adequately considered by the Nomination Committee.\n\nThe AGM 2027 in Camurus will be held at 5:00 pm CEST on 13 May 2027 in Lund.\nShareholders who want to have a matter addressed at the AGM 2027 must submit\nsuch a proposal to the same address as above (subject \"Annual General Meeting\n2027\") by 25 March 2027 at the latest.\n\nAbout Camurus\nCamurus is an international, science-led biopharmaceutical company committed\nto developing and commercializing innovative, long-acting medicines for\nimproving the lives of patients with severe and chronic diseases. New drug\nproducts with best-in-class potential are conceived based on the company's\nproprietary FluidCrystal(®) technology and its extensive R&D expertise. The\nR&D pipeline includes products for the treatment of dependence, pain, cancer,\nand endocrine diseases. Camurus has operations across Europe, the US, and\nAustralia, with headquarters in Lund, Sweden. The company's shares are listed\non Nasdaq Stockholm under the ticker CAMX. For more information, visit\nwww.camurus.com and LinkedIn (https://www.linkedin.com/company/Camurus).\n\nFor more information\nPer Olof Wallström, Chairman of the Board\nTel. +46 709 42 95 20\np.o.wallstrom@telia.com\n\nThe information was submitted for publication at 07:00 am CET on 11 September\n2026.\n\n\n\nhttps://news.cision.com/camurus-ab/r/camurus--nomination-committee-appointed-for-the-annual-general-meeting-2027%2Cc4394603\n\nPress release (https://mb.cision.com/Main/13456/4394603/4263634.pdf)\n\n\n\n(c) Cision 2026","article_body_html":"","raw_payload":{"data":{"id":"nWkr85c3LC-20260911","title":"Camurus' Nomination Committee appointed for the Annual General Meeting 2027","author":"Cision","ticker":"CAMX","created":"2026-09-11T05:00:14.359Z","tickers":["CAMX"],"exchange":"Nasdaq Stockholm","article_body":"Camurus AB\nLund, Sweden - 11 September 2026 - Camurus today announced that the Nomination\nCommittee for the Annual General Meeting (AGM) 2027 consists of the following\npersons, who together represent about 38 percent of the total number of shares\nand votes in Camurus based on the last known shareholder information:\n* Per Sandberg, appointed by Sandberg Development AB,\n* Arne Lööw, appointed by Fjärde AP-fonden,\n* Anna Henricsson, appointed by Handelsbanken Fonder, and\n* Per Olof Wallström, Chairman of the Board of Camurus\nThe Nomination Committee's proposals will be presented in the Notice to the\nAGM 2027 and on Camurus' website, www.camurus.com.\n\nShareholders who wish to submit proposals to the Nomination Committee are\nwelcome to contact the Nomination Committee at the company's address, Rydbergs\ntorg 4, SE-224 84, Lund, Sweden. Proposals shall be submitted in due time\nbefore the AGM, but not later than 11 February 2027, to ensure that the\nproposals can be adequately considered by the Nomination Committee.\n\nThe AGM 2027 in Camurus will be held at 5:00 pm CEST on 13 May 2027 in Lund.\nShareholders who want to have a matter addressed at the AGM 2027 must submit\nsuch a proposal to the same address as above (subject \"Annual General Meeting\n2027\") by 25 March 2027 at the latest.\n\nAbout Camurus\nCamurus is an international, science-led biopharmaceutical company committed\nto developing and commercializing innovative, long-acting medicines for\nimproving the lives of patients with severe and chronic diseases. New drug\nproducts with best-in-class potential are conceived based on the company's\nproprietary FluidCrystal(®) technology and its extensive R&D expertise. The\nR&D pipeline includes products for the treatment of dependence, pain, cancer,\nand endocrine diseases. Camurus has operations across Europe, the US, and\nAustralia, with headquarters in Lund, Sweden. The company's shares are listed\non Nasdaq Stockholm under the ticker CAMX. For more information, visit\nwww.camurus.com and LinkedIn (https://www.linkedin.com/company/Camurus).\n\nFor more information\nPer Olof Wallström, Chairman of the Board\nTel. +46 709 42 95 20\np.o.wallstrom@telia.com\n\nThe information was submitted for publication at 07:00 am CET on 11 September\n2026.\n\n\n\nhttps://news.cision.com/camurus-ab/r/camurus--nomination-committee-appointed-for-the-annual-general-meeting-2027%2Cc4394603\n\nPress release (https://mb.cision.com/Main/13456/4394603/4263634.pdf)\n\n\n\n(c) Cision 2026"},"type":"article","timestamp":"2026-09-11T05:00:14.445453342Z","server_sent_at_ms":1789102814445},"received_at":"2026-09-11T05:00:14.499Z","source_url":"https://news.cision.com/camurus-ab/r/camurus--nomination-committee-appointed-for-the-annual-general-meeting-2027%2Cc4394603"},"analysis":{"id":"130007","press_release_id":"141172","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Camurus has appointed its Nomination Committee for the 2027 Annual General Meeting, consisting of four members who together represent about 38 percent of the company's total shares and votes.\n\nThe committee comprises Per Sandberg (Sandberg Development AB), Arne Lööw (Fjärde AP-fonden), Anna Henricsson (Handelsbanken Fonder), and board chairman Per Olof Wallström.\n\nShareholder proposals to the Nomination Committee are due by 11 February 2027, and the AGM 2027 will be held on 13 May 2027 in Lund, Sweden.\n\nThis is a standard Swedish governance procedural announcement with no bearing on Camurus' pipeline, financials, or strategy.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine AGM 2027 governance housekeeping -- suppress or archive as low-signal."},"keyFigures":{"customDimensions":{"agm_date":"13 May 2027, 5:00 pm CEST, Lund","shareholder_representation":"38%","agm_matter_submission_deadline":"25 March 2027","nomination_committee_proposal_deadline":"11 February 2027"}},"namedEntities":{"people":[{"name":"Per Sandberg","role":"Nomination Committee member, appointed by Sandberg Development AB"},{"name":"Arne Lööw","role":"Nomination Committee member, appointed by Fjärde AP-fonden"},{"name":"Anna Henricsson","role":"Nomination Committee member, appointed by Handelsbanken Fonder"},{"name":"Per Olof Wallström","role":"Chairman of the Board of Camurus and Nomination Committee member"}],"products":["FluidCrystal"],"companies":[{"name":"Camurus AB","ticker":"CAMX","relationship":"filer/issuer"},{"name":"Sandberg Development AB","relationship":"major shareholder, nominating party"},{"name":"Fjärde AP-fonden","relationship":"shareholder, nominating party"},{"name":"Handelsbanken Fonder","relationship":"shareholder, nominating party"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine Swedish corporate-governance procedural step: appointment of the AGM 2027 Nomination Committee. No financial, operational, or strategic impact on Camurus."},"tickerRelevance":{"others":[],"primary":"CAMX"},"globalImportance":7,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap (Nasdaq Stockholm)","eventGravity":"routine-governance-procedural","sectorWeight":"biotech","issuerAuthored":true,"householdBrandBoost":0,"retailFavoriteBoost":0}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Camurus has appointed its Nomination Committee for the 2027 Annual General Meeting, consisting of four members who together represent about 38 percent of the company's total shares and votes.\n\nThe committee comprises Per Sandberg (Sandberg Development AB), Arne Lööw (Fjärde AP-fonden), Anna Henricsson (Handelsbanken Fonder), and board chairman Per Olof Wallström.\n\nShareholder proposals to the Nomination Committee are due by 11 February 2027, and the AGM 2027 will be held on 13 May 2027 in Lund, Sweden.\n\nThis is a standard Swedish governance procedural announcement with no bearing on Camurus' pipeline, financials, or strategy.","key_figures":{"customDimensions":{"agm_date":"13 May 2027, 5:00 pm CEST, Lund","shareholder_representation":"38%","agm_matter_submission_deadline":"25 March 2027","nomination_committee_proposal_deadline":"11 February 2027"}},"named_entities":{"people":[{"name":"Per Sandberg","role":"Nomination Committee member, appointed by Sandberg Development AB"},{"name":"Arne Lööw","role":"Nomination Committee member, appointed by Fjärde AP-fonden"},{"name":"Anna Henricsson","role":"Nomination Committee member, appointed by Handelsbanken Fonder"},{"name":"Per Olof Wallström","role":"Chairman of the Board of Camurus and Nomination Committee member"}],"products":["FluidCrystal"],"companies":[{"name":"Camurus AB","ticker":"CAMX","relationship":"filer/issuer"},{"name":"Sandberg Development AB","relationship":"major shareholder, nominating party"},{"name":"Fjärde AP-fonden","relationship":"shareholder, nominating party"},{"name":"Handelsbanken Fonder","relationship":"shareholder, nominating party"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-11T05:00:31.688Z","global_importance":7,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap (Nasdaq Stockholm)","eventGravity":"routine-governance-procedural","sectorWeight":"biotech","issuerAuthored":true,"householdBrandBoost":0,"retailFavoriteBoost":0}},"durationMs":17177,"modelName":"glm-5.3-flash"}}